2022 Global Conference Coverage: An Update on the Clinical Developments Across Gynecologic Malignancies*

Download All
2022; SGO, March; ASCO, June, ESMO, September; IGCS September; ESGO, October
Get up to date on emerging data in cervical, endometrial, and ovarian cancers presented at the 2022 meetings of SGO, ASCO, ESMO, IGCS, and ESGO with expert podcasts, commentaries, downloadable slides, and a “year in review” module.
Susana Banerjee, MBBS, MA, PhD, FRCP
Jubilee Brown, MD
person default
Elisabeth Diver, MD
person default
Alexandra Leary, MD, PhD
Domenica Lorusso, MD, PhD
David Scott Miller, MD, FACOG, FACS
person default
Mansoor Raza Mirza, MD
Prof Isabelle Ray-Coquard, MD, PhD
Angeles Alvarez Secord, MD, MHSc
Ignace Vergote, MD, PhD

Downloadable Slideset

Download this “living” summary slideset covering new data from key studies in gynecologic cancers as they are presented at different conferences throughout 2022.

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Released: November 10, 2022

Podcasts

In this podcast episode, listen to Prof Isabelle Ray-Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on trials of interest including novel HRD testing for ovarian cancer, OS results from ARIEL3, and QoL outcomes for rare nonepithelial ovarian cancers following chemotherapy.

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: November 30, 2022

In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss key updates for PARP inhibitor trials in ovarian cancer presented at the 2022 ESMO Congress, including the 7-year update from SOLO-1, final OS analyses for PAOLA-1, disease risk subgroup analysis from ATHENA-MONO, and OS results from ARIEL4.

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: October 4, 2022

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, discuss key data for gynecologic cancers presented at the 2022 SGO annual meeting, including data for novel agents in ovarian and endometrial cancers, and practical insights on recent approvals for cervical cancer.

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 19, 2022

In this podcast episode, listen to Jubilee Brown, MD, and Elisabeth Diver, MD, discuss new data for gynecologic cancers presented at the 2022 ASCO Annual Meeting, including practical insights on how they plan to use the new findings to inform their practice and emerging data for novel agents in endometrial cancers, and practical insights on recent approvals for cervical cancer.

Jubilee Brown, MD person default Elisabeth Diver, MD Released: June 30, 2022

In this podcast episode, listen to Susana Banerjee, MBBS, MA, PhD, FRCP, and Mansoor Raza Mirza, MD, share their thoughts on trials of interest for ovarian and cervical cancer presented at the IGCS 2022 Annual Global Meeting, including results from the highly anticipated CALLA trial, final OS analyses for ARIEL3, outcomes by previous lines of therapy from SOLO3, and results from the retrospective NeCTuR trial of topotecan, paclitaxel, and bevacizumab in neuroendocrine cervix cancer.

Susana Banerjee, MBBS, MA, PhD, FRCP person default Mansoor Raza Mirza, MD Released: October 24, 2022

ClinicalThought

In this commentary, expert faculty address frequently asked questions about integrating novel treatments for the management of patients with gynecologic cancers.

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 23, 2022

Two expert gynecologic oncologists answer frequently asked questions on the optimal use of new therapies in patients with endometrial, ovarian, and cervical cancer.

Jubilee Brown, MD person default Elisabeth Diver, MD Released: July 5, 2022

Two expert gynecologic oncologists discuss how to optimally use PARP inhibitors to treat patients with ovarian cancer.

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: October 19, 2022

Two experts in gynecologic cancers discuss important clinical trial updates, including chemoradiation, PARP inhibition, and checkpoint inhibitors.

Susana Banerjee, MBBS, MA, PhD, FRCP person default Mansoor Raza Mirza, MD Released: November 3, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Karyopharm Therapeutics
Merck Sharp & Dohme Corp.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings